Compare PRHI & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRHI | LEXX |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Canada |
| Employees | 9 | 7 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 16.2M |
| IPO Year | N/A | N/A |
| Metric | PRHI | LEXX |
|---|---|---|
| Price | $0.77 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 30.8K | ★ 180.1K |
| Earning Date | 05-13-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.46 |
| 52 Week High | $2.83 | $1.67 |
| Indicator | PRHI | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 64.93 |
| Support Level | $0.54 | $0.98 |
| Resistance Level | $0.87 | $1.05 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 82.34 | 83.33 |
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.